CSI Market
Sign In | Register

Omega Therapeutics Inc (OMGA) Quarterly Cash Flow Statement

Quarterly · GAAP · USD millions
Access OMGA Annual Cash Flow →
Looking at cash flow data from Omega Therapeutics Inc through Sep 30 2023 provides insight into Sep 30 2024's financial flexibility across reporting periods.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.
Quarterly Report, GAAP in USD millions
ITEM 		(Sep 30 2024)
9 Months 		(Jun 30 2024) (Mar 31 2024) (Dec 31 2023) (Sep 30 2023)
Operating Activities
Income-52.88
Depreciation & amortization1.32
Amortization of Other Assets0.04
Extraordinary Item, Gain (Loss), Insurance Assets, Accretion Expense0.00
Restructuring & Impairment Charges0.00
Provision For Loan Losses Expensed0.00
Inventories Decrease /-Increase0.00
R & D, Environmental and Other Expense0.00
Gain (Loss) on Disposition of Assets, Total0.00
Share-based Compensation6.37
Income (Loss) from Equity Method Investments0.00
Fair Value Adjustment of Warrants0.00
Change In Fair Value Of Success Fee Obligation-
Operating Lease Right Of Use Asset Amortization Expense4.21
Income taxes0.00
Losses/ -gains on Investments net0.00
Accounts Receivable5.65
Increase (Decrease) in Accounts Payable-0.19
Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities-3.91
Deferred Revenue and Customer Advances and Deposits0.00
Increase (Decrease) in Prepaid Expense and Other Assets2.58
Other Working Capital-1.67
Other Noncash Income (Expense)0.00
Other net0.00
Payments for (Proceeds from) Other Operating Activities0.00
Discontinued operations0.00
Net Cash flow from Operating Activities-38.49
Investing Activities
Capital Expenditures-0.95
Sale of Capital Items0.00
Proceeds from Maturities, Prepayments and Calls of Available-for-sale Securities5.00
Payments to Acquire Marketable Securities0.00
Real Estate Investments0.00
Restricted Cash and Investments Increase (Decrease)0.00
Payments for (Proceeds from) Loans0.00
Payments for (Proceeds from) Deposits0.00
Payments for (Proceeds from) Other Investments0.00
Payments for (Proceeds from) Federal Reserve and FHLB0.00
Acquisition Net of Cash Acquired0.00
Interest in Subsidiaries and Affiliates0.00
Sale of businesses0.00
Accounts payable0.00
Receivables0.00
Payments for (Proceeds from) Other Investing Activities0.00
Other Net0.00
Discontinued operations0.00
Net Cash Flow from Investing Activities4.05
Financing Activities
Short-term debt Net0.00
Other borrowing transactions0.00
Long-term debt - borrowings0.00
Long-term debt - repayments-3.33
Federal Home Loan Bank and Federal Funds0.00
Issuances / -repurchases of Comm. Stock0.02
Partnership and Parent Transactions0.00
Issuances / -repurchases of Pref. Stock0.00
Deposits, Annuities, Contract Holders Funds0.00
Other financing activities net0.00
Other net-68.78
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations68.78
Payment Of Success Fee-
Proceeds From Equity Offering-
Proceeds From Lease Financing-
Repayment Of Lease Financing-0.32
Payments of Dividends, Preferred Stock and Preference Stock0.00
Dividends paid0.00
Net Cash Flow from Financing Activities-3.63
Effect of exchange rate on cash flow0.00
Discontinued operations0.00
Free Cash Flow-39.44
Total Cash Flow-38.07
4 historic quarters locked

Sign in to unlock the full Omega Therapeutics Inc cash flow history.

Sign In Create Free Account

About Omega Therapeutics Inc Quarterly Cash Flow Statement

What this statement shows

This page presents issuer-reported cash flow data, including operating, investing, financing, net, and free cash flow, as disclosed in SEC 10-Q filings and normalized by CSIMarket.

Source & verification

  • Form: 10-Q (Period: 20240930)
  • Filed with the SEC: November 14, 2024
  • Source: omga-20240930.htm

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - normalization in the CSIMarket.com database.
  • Accession: 0000950170-24-127008

Figures are derived from filed reports and may be restated. Historical data is subject to revision.